Characterization and identification of protein O-GlcNAcylation sites with substrate specificity
2014 · BMC Bioinformatics · 35 citations
https://doi.org/10.1186/1471-2105-15-s16-s1
H
Hui-Ju Kao
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
11
Papers
357
Citations
4
h-index
4
i10-index
Hui-Ju Kao is an academic researcher from Mackay Memorial Hospital. The author has contributed to research in topics: SARS-CoV-2 and COVID-19 Research & Immunotherapy and Immune Responses & Machine Learning in Bioinformatics. The author has an h-index of 4, co-authored 10 publications.
ORCID: 0000-0001-6109-0319Papers by this author
worksA SARS-CoV-2 spike-derived adjuvant peptide boosts IL-17/IFN-γ immunity and improves anti-PD-L1 therapy against melanoma
2025 · Figshare · 0 citations
https://doi.org/10.6084/m9.figshare.c.8220691
Additional file 1 of A SARS-CoV-2 spike-derived adjuvant peptide boosts IL-17/IFN-γ immunity and improves anti-PD-L1 therapy against melanoma
2025 · Figshare · 0 citations
https://doi.org/10.6084/m9.figshare.30959344.v1
A SARS-CoV-2 spike-derived adjuvant peptide boosts IL-17/IFN-γ immunity and improves anti-PD-L1 therapy against melanoma
2025 · Figshare · 0 citations
https://doi.org/10.6084/m9.figshare.c.8220691.v1
Additional file 1 of A SARS-CoV-2 spike-derived adjuvant peptide boosts IL-17/IFN-γ immunity and improves anti-PD-L1 therapy against melanoma
2025 · Figshare · 0 citations
https://doi.org/10.6084/m9.figshare.30959344
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat